Erick Gamelin, M.D., Ph.D., is Chief Development Officer at Acrivon Therapeutics, Inc. From 2019 to 2021, he served as Chief Medical Officer at Step Pharma, a biotech focused on developing drugs in hematological malignancies. Previously he served as Vice President, Oncology at Dynavax Technologies focused on oncology vaccines and immune therapies, and prior to that as Vice President at Macrogenics Inc., working with immune therapies and bispecifics. Before that, he held leadership positions in early development at the Oncology Vaccine department at Pfizer, and with Targeted Therapies at Amgen.
Erick is a Medical Oncologist and Pharmacologist, former Professor of Oncology, and CEO of a national university cancer center and hospital, the West Oncology Institute. He received the title of Chevalier in the National Order of Merit by the French Minister of Health. During his career in academia, he has led a research lab in oncogenomics and genetics, funded by the French NCI, focused on the mechanisms of acquired resistance of cancer cells. He received his Ph.D. in molecular pharmacology from Bordeaux University and did his Post-Doc at the NIH, Molecular Therapeutics Section, Medical Oncology Branch. He has led over 100 Phase 1-3 oncology trials and coauthored more than 135 articles in peer-reviewed international journals.